

annen annen tinten 1. 10. 10. 10. 10. 10. **OSSUR INVESTOR MEETING Q2 2009**

1



Q2 2009

JON SIGURDSSON – PRESIDENT & CEO

N 18 18 18 18 18

HIGHLIGHTS FOR THE QUARTER



Stable Sales

- Slowdown of economy
- Third party suppliers discontinued
- Promising Bionic upgrades coming up
- New structure of US sales channel in bracing and supports



Profitability Maintained - EBITDA 21%, remains stable



Strong Bionic Product Pipeline

- Reimbursement of PROPRIO FOOT accepted in the US
- PROPRIO FOOT, scale up in manufacturing and full launch in the second half of the year
- RHEO KNEE II, pre-launched, full market release in the second half of the year

PRODUCT LAUNCHES Q2 2009 – DIVERSE PRODUCT PIPELINE

ÖSSUR . Life Without Limitations

Four new products launched in Q2



Unloader One® Short

Sensil liners on Unloader

Vari-Flex EVO

Iceross Cushion & Sleeve

- A new version of the Bionic knee RHEO KNEE II, pre-launched
- PROPRIO foot accepted into the US reimbursement channel

Important milestones for the future of the Bionic platform

MARKETS AND ENVIRONMENT Q2 2009





•• Americas

- → Slowdown of economy
 - \rightarrow Region specific
 - \rightarrow Trend towards low-price products
- \rightarrow Strong sales leadership in place
- \rightarrow 12 new sales reps in B&S
- → Further GPO opportunities

•• EMEA

- \rightarrow Slowdown of economy
 - \rightarrow UK private pay
 - → France and Spain
 - → Other markets less affected
- \rightarrow Third party suppliers, contracts discontinued

Asia

- → Slowdown of economy
 - \rightarrow Korea, significant effect
 - \rightarrow Australia, China and Japan on track


DEVELOPMENT IN SEGMENTS AND GEOGRAPHY




SEGMENTS				
Local currency	Q2	YTD		
Prosthetics	2%	3%		
Bracing and supports	-6%	-7%		
Compression therapy	-12%	-10%		
Total	-3%	-3%		
Avg. sales growth pr day	-1%	-2%		

GEOGRAPHY

Local currency	Q2	YTD
Americas	1%	-3%
EMEA	-7%	-4%
Asia	2%	6%
Total	-3%	-3%
Avg. sales growth pr day	-1%	-2%







Life Without Limitations

FINANCIALS: Q2 2009

HJORLEIFUR PALSSON - CFO

FINANCIAL HIGHLIGHTS Q2 2009





- Solid operations
- Strong balance sheet
- Secured financing

INCOME STATEMENTS Q2 2009




Income Statements (USD '000)	Q2 2009	% of sales	Q2 2008	% of sales	Change
Net sales	81,345	100.0%	92,055	100.0%	-11.6%
Cost of goods sold	(31,284)	-38.5%	(35,656)	-38.7%	-12.3%
Gross profit	50,061	61.5%	56,399	61.3%	-11.2%
Other income	120	0.1%	1,264	1.4%	-90.5%
Sales & marketing expenses	(23,105)	-28.4%	(25,540)	-27.7%	-9.5%
Research & development expenses	(4,813)	-5.9%	(5,379)	-5.8%	-10.5%
General & administrative expenses	(10,490)	-12.9%	(14,000)	-15.2%	-25.1%
Profit from operations	11,774	14.5%	12,744	13.8%	-7.6%
Financial income	70	0.1%	105	0.1%	-33.3%
Financial expenses	(7,416)	-9.1%	(5,200)	-5.6%	42.6%
Profit before tax	4,428	5.4%	7,649	8.3%	-42.1%
Income tax	(927)	-1.1%	(3,705)	-4.0%	-75.0%
Net profit for the period	3,501	4.3%	3,944	4.3%	-11.2%
EBITDA	16,961	20.9%	19,038	20.7%	-10.9%
EBITDA adjusted*	17,930	22.0%	19,238	20.7%	-6.8%

*Adjusted for one-time income and expenses

SALES – MATERIAL CURRENCY IMPACT






GROSS PROFIT – STABLE MARGINS








OPERATING EXPENSES – SAME COST STRUCTURE






- Operating expense ratio improves slightly: 47.2% vs. 48.8%
- Adjusted for currency effects and severance the ratio remains the same
- R&D slightly up G&A slightly down
- Profit from operations as ratio to sales 14.5%


FINANCIAL EXPENSES – CURRENCY SWING



NET INTEREST EXPENSE




EXCHANGE RATE DIFFERENCES



- Interest expenses down USD 1.8 million
- Exchange rate losses up USD 4.0 million
- Net increase in financial expenses USD 2.2 million


NET PROFIT – OSSUR IS PROFITABLE





CASH EARNINGS PER SHARE - INCREASES









CASH FLOW – REMAINS STRONG





CAPEX – WITHIN BENCHMARK





BALANCE SHEETS 30 JUNE 2009



USD '000	30 June 2009	31 Dec 2008
Non current assets	457,563	458,046
Current assets	141,316	145,732
Total assets	598,879	603,778
Stockholders' equity	264,727	249,648
Non current liabilities	258,820	223,242
Current liabilities	75,332	130,888
Total equity and liabilities	598,879	603,778
Current ratio	1.9	1.1
Equity ratio	44%	41%
Net Debt / EBITDA	3.2	2.9

- Cash at hand USD 35.7 million
- No working capital issues
- Long term financing in place at favorable terms
- No covenant issues

FINANCIAL HIGHLIGHTS Q2 2009





- Solid operations
- Strong balance sheet
- Secured financing

MARKET GUIDANCE FOR 2009



FULL YEAR 2009

Sales USD 310-320 million EBITDA USD 58-62 million EBITDA margin 18% -19%

Jon Sigurdsson, President & CEO, comments:

"Slowdown of the economy in the Company's major markets has affected sales, as customers are cautious due to uncertainty. Discontinuation of third party agreements in EMEA has a temporary negative effect on sales but not on profitability. Strong leadership and clear strategy in sales and marketing in the US give comfort towards positive developments. A new version of the bionic knee Rheo as well as the acceptance of the Proprio foot into the US reimbursement channel are important milestones for the future of the bionic platform."

HIGHLIGHTS FOR THE QUARTER



Stable Sales

Profitability Maintained

Strong Bionic Product Pipeline

